GlobeNewswire Inc.··Not SpecifiedAndera Partners Backs Rivermark Medical's $20M Series D to Advance BPH Treatment
Andera Partners leads $20M Series D funding for Rivermark Medical's FloStent System, a non-surgical benign prostatic hyperplasia treatment advancing toward FDA approval.
ACGRFDA approvalclinical trial